a nonsignificant trendP = 0.083
found a nonsignificant trend towards improved 12-month clinical outcomes ( P = 0.083) for patients who received IV magnesium infusion but noted significant side effects including hypocalcemia ( P = 0.005) and hypotension ( P = 0.04) [ 41 ].